CBDMD INC (YCBD)
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$0.48-1.12%
Close 2026-09-04 · 1-day change
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · YCBD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Grow revenue and diversify product categories by acquiring established supplement and wellness brands like Twinlab to broaden market reach beyond hemp-derived products.
Newly stated in 2026-Q3. The acquisition of Twinlab brands is expected to increase cbdMD’s revenue by approximately 40% to about $30 million trailing twelve months as of June 2026, diversifying beyond hemp-derived products. This marks a strategic expansion into broader consumer wellness categories, with no prior quarters stating this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women’s Beauty, Weight Loss and Longevity Wellness”
Maintain operational stability by extending the lease of the warehouse and executive offices in Charlotte, North Carolina.
Newly stated in 2026-Q2. The company extended its warehouse lease for 62 months starting October 1, 2026, ensuring operational continuity. This is a one-time lease extension with no prior quarters mentioning this priority.
“cbdMD entered into a Third Amendment to Lease to extend the Warehouse Lease for 62 months beginning October 1, 2026”
Navigate capital allocation challenges following new financial obligations, including those related to acquisitions and lease amendments.
Newly stated in 2026-Q2. The company disclosed new financial obligations impacting capital allocation, coinciding with acquisition and lease activities. No prior quarters referenced this priority, indicating a recent focus on managing capital amid these obligations.
“Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant”
Roll out new equity compensation plans and executive employment agreements to support talent retention and alignment.
Newly stated in 2026-Q1. The company approved new equity compensation and executive agreements to support talent management. This priority has not been restated in subsequent quarters, indicating a recent but singular focus.
“Approval of a new equity compensation plan and an executive employment agreement”
Over the trailing year it converted 0.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar (low R² over the window).
14 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.